{"product_id":"quipthomemedical-pestle-analysis","title":"Quipt Home Medical PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, reimbursement trends, and rapid medtech innovation are shaping Quipt Home Medical’s prospects—our concise PESTLE snapshot highlights risks and opportunities you can act on today; purchase the full PESTLE for a complete, ready-to-use strategic briefing and downloadable templates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal Reimbursement Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Centers for Medicare and Medicaid Services refined competitive bidding and DME fee schedules through late 2025, with proposed rate cuts averaging 8–12% for certain respiratory supplies, directly compressing margins for home respiratory and sleep therapy providers like Quipt.\u003c\/p\u003e\n\u003cp\u003eMedicare covers roughly 70% of home respiratory device reimbursements; a 10% rate reduction could cut Quipt’s DME revenue by an estimated $6–12 million annually based on 2024 revenue trends.\u003c\/p\u003e\n\u003cp\u003eQuipt must sustain an active government relations strategy—engaging CMS rulemaking, participating in supplier bidding, and lobbying Congress—to mitigate risks from budget-driven restructuring or further reimbursement reductions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBipartisan Support for Aging in Place\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThere is bipartisan momentum into 2026 to move care from institutions to home, supported by CMS data showing Medicare spends about 34% more per beneficiary in institutional settings versus home-based care, and by 2024–25 federal proposals expanding remote therapeutic monitoring and home health payment models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Relations and Medical Supply Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical stability and trade agreements shape costs and availability of Quipt's internationally manufactured devices; tariffs can raise input costs by 5–12% on average for medical imports. Ongoing 2025 geopolitical tensions have produced periodic tariff hikes—notably a 10% tariff on some respiratory equipment and 8% on electronic monitoring components—pressuring margins. Quipt must diversify suppliers across at least three regions to mitigate supply shocks and inventory disruption risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState Level Licensing and Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuipt must navigate state-by-state licensing for respiratory therapists and DME suppliers; 27 states updated telehealth or DME rules in 2023–2025, increasing compliance costs and administrative headcount.\u003c\/p\u003e\n\u003cp\u003eState political shifts can alter Medicaid eligibility—Medicaid covers ~40% of home respiratory patients nationally—so changes in expansion or reimbursement rates materially affect regional revenue.\u003c\/p\u003e\n\u003cp\u003eContinuous monitoring of 50 state legislative sessions is essential to avoid service interruptions and maintain a multi-state footprint; noncompliance risks license suspension and lost revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e27 states changed DME\/telehealth rules (2023–2025)\u003c\/li\u003e\n\u003cli\u003eMedicaid covers ~40% of home respiratory patients\u003c\/li\u003e\n\u003cli\u003eActive monitoring of 50 state legislatures required\u003c\/li\u003e\n\u003cli\u003eNoncompliance risk: license suspension and revenue loss\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Focus on Healthcare Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIncreased political scrutiny of healthcare consolidation has raised antitrust reviews; DOJ and FTC blocked or sued over 12 hospital\/healthcare deals in 2023–2024, signaling tougher enforcement that affects Quipt’s M\u0026amp;A strategy.\u003c\/p\u003e\n\u003cp\u003eAs Quipt acquires regional providers, regulators focus on market dominance and potential price effects—transactions showing measurable improvements in access and cost (e.g., 10–15% unit-cost reductions or expanded service coverage) gain favorable review.\u003c\/p\u003e\n\u003cp\u003eDocumenting post-acquisition metrics—patient access, referral patterns, price trends—and targeting deals in under-served ZIP codes reduces regulatory risk and increases chances of approval amid a cautious political climate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDOJ\/FTC actions: 12+ notable healthcare enforcement actions in 2023–2024\u003c\/li\u003e\n\u003cli\u003eTarget proof points: ≥10% cost reduction or measurable access expansion\u003c\/li\u003e\n\u003cli\u003eStrategy: prioritize acquisitions in under-served markets to mitigate antitrust concerns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuipt revenue hit: Medicare cuts ~10%, tariffs \u0026amp; regs raise costs amid rising antitrust risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCMS DME cuts (proposed 8–12% through 2025) risk reducing Quipt’s Medicare-driven revenue ~10% (~$6–12M based on 2024 trends); Medicaid changes matter (covers ~40% of patients). Tariffs (2025: ~8–10% on respiratory\/electronics) and 27 state DME\/telehealth rule changes (2023–25) raise costs and compliance headcount; DOJ\/FTC pursued 12+ healthcare antitrust actions (2023–24), tightening M\u0026amp;A scrutiny.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare share of DME\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Medicare rate cut\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated revenue impact\u003c\/td\u003e\n\u003ctd\u003e$6–12M (2024 baseline)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid patient share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStates updating rules (2023–25)\u003c\/td\u003e\n\u003ctd\u003e27\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff impact\u003c\/td\u003e\n\u003ctd\u003e8–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDOJ\/FTC actions (2023–24)\u003c\/td\u003e\n\u003ctd\u003e12+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal factors uniquely affect Quipt Home Medical, with each section backed by current market and regulatory data to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClean, succinct PESTLE summary tailored for Quipt Home Medical that’s visually segmented for quick reference, easily droppable into presentations, editable for regional\/context notes, and shareable across teams to streamline risk discussions and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Impact on Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2025 raised labor, fuel, and supply costs; U.S. CPI averaged 4.0% in 2024 and wage growth for healthcare occupations hit ~4.5% year-over-year, pressuring Quipt's certified respiratory therapist salaries and home-delivery fuel\/maintenance costs (fuel up ~15% vs 2023). With Medicare\/Medicaid reimbursement largely fixed, Quipt must drive operational efficiencies to offset margin compression and protect EBITDA. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Growth Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, the US federal funds rate near 5.25–5.50% raises Quipt’s cost of capital, making debt-funded roll-ups pricier and increasing annual interest expense on a $100m deal by roughly $5–5.5m. Management has therefore rebalanced toward organic growth and pursuing only highly accretive M\u0026amp;A targets with projected cash-on-cash payback under 24 months and clear integration synergies to preserve free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Spending and Healthcare Affordability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic conditions affecting household disposable income influence patients' ability to meet co-payments and deductibles for sleep apnea and oxygen therapy; US personal consumption expenditures rose 3.5% in 2024 while median household real income fell 1.2%, raising bad-debt risk. Even as CPAP and oxygen are medically necessary, downturns can delay treatment or reduce compliance—CMS data show a 5–8% drop in elective DME uptake in 2023–24 in weaker regions. Quipt tracks regional unemployment and median income to forecast patient volume and bad-debt expense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost Efficiency of Home Based Care Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe push by US private insurers and CMS toward value-based care and lower medical loss ratios makes home-based care economically attractive; home medical equipment and remote monitoring reduce average post-acute costs by up to 30% versus SNF stays, with hospital readmission reductions of 20–25% reported in 2023–2024 pilots.\u003c\/p\u003e\n\u003cp\u003eFor payers facing rising inpatient costs, Quipt’s HME and remote monitoring can lower per-patient episode spend, supporting goals to cut MLRs while preserving outcomes; the HME market grew ~8% CAGR to $20B in 2024, underscoring payer demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHome care can cut post-acute costs ~30%\u003c\/li\u003e\n\u003cli\u003eReadmissions down 20–25% in recent pilots\u003c\/li\u003e\n\u003cli\u003eHME market ~ $20B in 2024, ~8% CAGR\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Dynamics in Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa shortage of qualified healthcare professionals especially in respiratory care intensified by data showing a regional gap therapists has made talent acquisition highly competitive for quipt.\u003e\u003cpquipt must invest in higher compensation increases of salaries career development programs to retain clinicians central its service model.\u003e\u003cphigh turnover with industry estimates of replacement costs between annual salary poses a significant economic risk requiring strategic hr interventions.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15–20% regional shortage in respiratory therapists (2024–2025)\u003c\/li\u003e\n\u003cli\u003eMarket pay up 8–12% in 2024 for specialized clinicians\u003c\/li\u003e\n\u003cli\u003eTurnover replacement costs 20–150% of salary\u003c\/li\u003e\n\u003cli\u003eNeed for compensation, training, and retention programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phigh\u003e\u003c\/pquipt\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising costs, staffing gaps squeeze HME margins—efficiency and selective M\u0026amp;A required\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation-warmed input costs and 5.25–5.50% fed funds raise operating and financing costs; 2024 U.S. CPI 4.0% and healthcare wage growth ~4.5%; HME market ~$20B (2024, ~8% CAGR); median real household income down 1.2% (2024) raising bad-debt risk; respiratory therapist regional shortfall 15–20% and pay +8–12% (2024), pressuring margins and necessitating efficiency and selective M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. CPI\u003c\/td\u003e\n\u003ctd\u003e4.0% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50% (late 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHME market\u003c\/td\u003e\n\u003ctd\u003e$20B, 8% CAGR (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRT shortage\u003c\/td\u003e\n\u003ctd\u003e15–20% (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eQuipt Home Medical PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Quipt Home Medical PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use. This snapshot reflects the real file, with complete content and professional structure, not a teaser or placeholder. After payment you’ll instantly download the same finished document shown here, so you can apply the PESTLE insights immediately. Everything displayed is part of the final deliverable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751410512249,"sku":"quipthomemedical-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/quipthomemedical-pestle-analysis.png?v=1772231059","url":"https:\/\/growthsharematrix.com\/products\/quipthomemedical-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}